Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
A randomized, multicenter, Phase I/IIa clinical study to evaluate the tolerability, safety, efficacy, pharmacokinetics and immunogenicity after single/multiple administration of recombinant anti-HER2 humanized monoclonal antibody for injection for the treatment of HER2-positive breast cancer patients.
HER2-positive Breast Cancer
BIOLOGICAL: GB221,2 mg/kg|BIOLOGICAL: GB221,6 mg/kg|BIOLOGICAL: Herceptin,6 mg/kg|BIOLOGICAL: GB221,8mg/kg|BIOLOGICAL: GB221:2mg/kg and Capecitabi:1000mg/kg|BIOLOGICAL: Herceptin:2mg/kg and Capecitabin:1000mg/kg
maximum tolerated dose,MTD, To evaluate the efficacy and safety of GB221., Up to 5 weeks|C max, C max, Up to 5 weeks|AUC (0- t), AUC (0- t), Up to 5 weeks|AUC (0- ∞ ), AUC (0- ∞ ), Up to 5 weeks|T max, T max, Up to 5 weeks|T 1/2, T 1/2, Up to 5 weeks|CL/F, CL/F, Up to 5 weeks|V/F, V/F, Up to 5 weeks|K e, K e, Up to 5 weeks
Antidrug antibody, ADA, Antidrug antibody, ADA, Up to 5 weeks
A randomized, multicenter, Phase I/IIa clinical study to evaluate the tolerability, safety, efficacy, pharmacokinetics and immunogenicity after single/multiple administration of recombinant anti-HER2 humanized monoclonal antibody for injection for the treatment of HER2-positive breast cancer patients.